Skip to content
value.today
Hepion Pharmaceuticals, Inc. logo

Hepion Pharmaceuticals, Inc.

🇺🇸 Red Bank, New Jersey, USABiotechnologyFounded 2013
Total raised
$17 M
3 rounds on record
Latest round
$9 M
Oct 2014
First round on record
Feb 2014
Today
Went public
See the company page

Hepion Pharmaceuticals, Inc. is listed today as Hepion Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Hepion Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2026$3 MPrivate placement after listing$2 to $10 million

Hepion Pharmaceuticals, Inc.: Private sale, Jul 2026

Investors in this round

33 investors had bought by the notice of Aug 5, 2026: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary Stetz · Executive Officer, Director · Interim Chief Executive Officer
  • Vincent LoPriore · Executive Officer, Director · Executive Chairman
  • Chase LoPriore · Director
  • Dania Fisher · Director
  • Gary S. Stetz, II · Director
  • Michael Purcell · Director
  • Sireesh Appajosyula · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Not applicable. · UnknownSold in all US states

Signed by Gary Stetz, Interim Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 5, 2026. Read the notice at the SEC.

equity, optionsSEC
Jul 2024$3 MPrivate placement after listing$2 to $10 million

Hepion Pharmaceuticals, Inc.: Private sale, Jul 2024

Investors in this round

7 investors had bought by the notice of Jul 24, 2024: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$175,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Cavan · Executive Officer · Interim Chief Executive Officer and Chief Financial Officer
  • John P. Brancaccio · Director
  • Kaouthar P. Lbiati · Director
  • Michael P. Purcell · Director
  • Timothy P. Block · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • A.G.P./Alliance Global Partners (CRD 000008361) · Westport, ConnecticutSold in FL, NV, NY, and outside the US
  • Laidlaw & Company (UK) Ltd. (CRD 000119037) · New York, New YorkSold in FL, NV, NY, and outside the US

Remarks in the notice

  • On fees: “$52,500 of the reported sales commission was paid to A.G.P./Alliance Global Partners and $122,500 of the reported sales commission was paid to Laidlaw & Company (UK) Ltd.”

Signed by John Cavan, Interim Chief Executive Officer and Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 24, 2024. Read the notice at the SEC.

equity, debtSEC
Sep 2023$5 MPrivate placement after listing$2 to $10 million

Hepion Pharmaceuticals, Inc.: Private sale, Sep 2023

Investors in this round

1 investor had bought by the notice of Oct 3, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$399,996
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Cavan · Executive Officer · Chief Financial Officer
  • Robert Foster · Executive Officer, Director · Chief Executive Officer and Director
  • Anand Reddi · Director
  • Gary S. Jacob · Director
  • John P. Brancaccio · Director
  • Kaouthar P. Lbiati · Director
  • Petrus P. Wijngaard · Director
  • Timothy P. Block · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • A.G.P./Alliance Global Partners (CRD 8361) · Westport, ConnecticutSold in NY

Signed by Robert Foster, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 3, 2023. Read the notice at the SEC.

equity, optionsSEC
Nov 2022$20 MPrivate placement after listing$10 to $50 million

Hepion Pharmaceuticals, Inc.: Private sale, Nov 2022

Investors in this round

8 investors had bought by the notice of Nov 15, 2022: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Sale and issuance of Series F preferred stock and Series G preferred stock and the underlying shares of Common Stock issuable upon the conversion thereof
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Cavan · Executive Officer · Chief Financial Officer
  • Robert Foster · Executive Officer, Director · Chief Executive Officer and Director
  • Todd Hobbs · Executive Officer · Chief Medical Officer
  • Arnold P. Lippa · Director
  • Gary S. Jacobs · Director
  • John P. Brancaccio · Director
  • Petrus P. Wijngaard · Director
  • Timothy P. Block · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • A.G.P./ Alliance Global Partners (CRD 8361) · Westport, ConnecticutSold in all US states

Signed by Robert Foster, Chief Executive Officer, Director. Source: SEC Form D, newest notice filed Nov 15, 2022. Read the notice at the SEC.

equitySEC
Mar 2019$1 MPrivate placement after listingUnder $2 million

Hepion Pharmaceuticals, Inc.: Private sale, Mar 2019

Investors in this round

1 investor had bought by the notice of Mar 27, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John P. Cavan · Executive Officer
  • Robert Foster · Executive Officer, Director
  • Arnold P. Lippa · Director
  • Gary S. Jacob · Director
  • John P. Brancaccio · Director
  • Thomas P. Adams · Director
  • Timothy P. Block · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Cavan, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 27, 2019. Read the notice at the SEC.

equity, debtSEC
Oct 2014$9 MNo. 3$2 to $10 million

Hepion Pharmaceuticals, Inc.: Raise no. 3, Oct 2014

Investors in this round

1 investor had bought by the notice of Oct 23, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $13 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bill Hornung · Executive Officer
  • James Sapirstein · Executive Officer, Director
  • Christopher McGuigan · Director
  • Gary Jacob · Director
  • John Brancaccio · Director
  • Timothy Block · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Sapirstein, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 23, 2014. Read the notice at the SEC.

equitySEC
Aug 2014$5 MNo. 2$2 to $10 million

Hepion Pharmaceuticals, Inc.: Raise no. 2, Aug 2014

Investors in this round

19 investors had bought by the notice of Aug 22, 2014: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bill Hornung · Executive Officer
  • James Sapirstein · Executive Officer, Director
  • Christopher McGuigan · Director
  • Gary Jacob · Director
  • John Brancaccio · Director
  • Timothy Block · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Sapirstein, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 22, 2014. Read the notice at the SEC.

equitySEC
Feb 2014$3 MNo. 1$2 to $10 million

Hepion Pharmaceuticals, Inc.: Raise no. 1, Feb 2014

Investors in this round

19 investors had bought by the notice of Feb 14, 2014: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernard F. Denoyer · Executive Officer, Director
  • Gary S. Jacob · Executive Officer, Director
  • Christopher P. McGuigan · Director
  • John P. Brancaccio · Director
  • Timothy P. Block · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds to pay salaries to its officers and directors.”

Signed by Gary S. Jacob, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 14, 2014. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Hepion Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2026).

    SEC Form D · Aug 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2026

That is all the official record says: Hepion Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Hepion Pharmaceuticals, Inc. are on record.

Investors#

No investor of Hepion Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 19 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Hepion Pharmaceuticals, Inc.
NameRoleNamed in
Gary StetzInterim Chief Executive OfficerAug 2026
Vincent LoPrioreExecutive ChairmanAug 2026
John CavanInterim Chief Executive Officer and Chief Financial OfficerJul 2024
Robert FosterChief Executive Officer and DirectorOct 2023
Todd HobbsChief Medical OfficerNov 2022
John P. CavanExecutive officerMar 2019
Bill HornungExecutive officerOct 2014
James SapirsteinExecutive officerOct 2014
Bernard F. DenoyerExecutive officerFeb 2014
Gary S. JacobExecutive officerFeb 2014
Chase LoPrioreDirectorAug 2026
Dania FisherDirectorAug 2026
Gary S. Stetz, IIDirectorAug 2026
Gary StetzInterim Chief Executive OfficerAug 2026
Michael PurcellDirectorAug 2026
Sireesh AppajosyulaDirectorAug 2026
Vincent LoPrioreExecutive ChairmanAug 2026
John P. BrancaccioDirectorJul 2024
Kaouthar P. LbiatiDirectorJul 2024
Michael P. PurcellDirectorJul 2024
Timothy P. BlockDirectorJul 2024
Anand ReddiDirectorOct 2023
Gary S. JacobDirectorOct 2023
Petrus P. WijngaardDirectorOct 2023
Robert FosterChief Executive Officer and DirectorOct 2023
Arnold P. LippaDirectorNov 2022
Gary S. JacobsDirectorNov 2022
Thomas P. AdamsDirectorMar 2019
Christopher McGuiganDirectorOct 2014
Gary JacobDirectorOct 2014
James SapirsteinDirectorOct 2014
John BrancaccioDirectorOct 2014
Timothy BlockDirectorOct 2014
Bernard F. DenoyerDirectorFeb 2014
Christopher P. McGuiganDirectorFeb 2014

Went public since 2016. Its SEC number is that of a company listed on a stock exchange.